Two big news highlights. Each has major impacts o
Post# of 36563
(Total Views: 421)
Posted On: 09/01/2021 2:26:24 PM
Two big news highlights. Each has major impacts overall to the wellbeing of the company.
Each well over a month old. These are just two items that are a focal point that affect the PPS of the company and the concern of shareholders and even future investors as to what is going on within Generex / NGIO at the moment.
Last PR from Generex was on 7/26
Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA
Last SEC filing was on 7/23
On July 22, 2021, Generex Biotechnology Corporation (“Generex”) on behalf of itself and its subsidiary NuGenerex Immuno-Oncology, Inc. (collectively “Generex”) entered into a Quality Agreement with PPD Development, L.P. (“PPD”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 coronavirus peptide vaccine (the “Quality Agreement”). The Quality Agreement describes the standards, expectations, and responsibilities of Generex and PPD with respect to managing quality, including, but not limited to, quality assurance (QA) and quality risk management (QRM) for the services and/or deliverables.
Each well over a month old. These are just two items that are a focal point that affect the PPS of the company and the concern of shareholders and even future investors as to what is going on within Generex / NGIO at the moment.
Last PR from Generex was on 7/26
Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA
Last SEC filing was on 7/23
On July 22, 2021, Generex Biotechnology Corporation (“Generex”) on behalf of itself and its subsidiary NuGenerex Immuno-Oncology, Inc. (collectively “Generex”) entered into a Quality Agreement with PPD Development, L.P. (“PPD”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 coronavirus peptide vaccine (the “Quality Agreement”). The Quality Agreement describes the standards, expectations, and responsibilities of Generex and PPD with respect to managing quality, including, but not limited to, quality assurance (QA) and quality risk management (QRM) for the services and/or deliverables.
(0)
(0)